Achilles Therapeutics plc
DelistedCIK 1830749fmd_0HB5PJ8WJNW8VV34PR4672234GManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Jun 30, 2024, 11 periods
Latest annual · FY2023
Millions- Operating income
- (75)
- Net income
- (70)
- Free cash flow
- (50)
Latest quarter · Q2 FY2024
Millions- Operating income
- (18)
- Net income
- (16)
Achilles Therapeutics plc financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Operating income | -$75.3 million | -$78.4 million | 20-F 2024-04-04 · proof | |
| Net income | -$69.7 million | -$71.2 million | 20-F 2024-04-04 · proof | |
| Cash from operating activities | -$48.4 million | -$59.5 million | 20-F 2024-04-04 · proof | |
| Free cash flow | -$49.5 million | -$67 million | 20-F 2024-04-04 · proof | |
| Total assets | $161.5 million | $220.4 million | -26.7% | 20-F 2024-04-04 · proof |
| Total liabilities | $19.1 million | $23.3 million | -18.1% | 20-F 2024-04-04 · proof |
| Cash and cash equivalents | $131.5 million | $173.3 million | -24.1% | 20-F 2024-04-04 · proof |
- What was Achilles Therapeutics plc's operating income in fiscal 2023?
- Achilles Therapeutics plc reported operating income of -$75.3 million for fiscal 2023 (the year ended Dec 31, 2023), against -$78.4 million the year before. Source: the 20-F filed with the SEC on Apr 4, 2024. SEC
- What was Achilles Therapeutics plc's net income in fiscal 2023?
- Achilles Therapeutics plc reported net income of -$69.7 million for fiscal 2023 (the year ended Dec 31, 2023), against -$71.2 million the year before. Source: the 20-F filed with the SEC on Apr 4, 2024. SEC
- What was Achilles Therapeutics plc's cash from operating activities in fiscal 2023?
- Achilles Therapeutics plc reported cash from operating activities of -$48.4 million for fiscal 2023 (the year ended Dec 31, 2023), against -$59.5 million the year before. Source: the 20-F filed with the SEC on Apr 4, 2024. SEC
- What was Achilles Therapeutics plc's free cash flow in fiscal 2023?
- Achilles Therapeutics plc reported free cash flow of -$49.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$67 million the year before. Source: the 20-F filed with the SEC on Apr 4, 2024. SEC
- What are Achilles Therapeutics plc's total assets?
- As of Dec 31, 2023, Achilles Therapeutics plc reported total assets of $161.5 million, against $220.4 million a year earlier (-26.7%). Source: the 20-F filed with the SEC on Apr 4, 2024. SEC
- What are Achilles Therapeutics plc's total liabilities?
- As of Dec 31, 2023, Achilles Therapeutics plc reported total liabilities of $19.1 million, against $23.3 million a year earlier (-18.1%). Source: the 20-F filed with the SEC on Apr 4, 2024. SEC
- What are Achilles Therapeutics plc's cash and cash equivalents?
- As of Dec 31, 2023, Achilles Therapeutics plc reported cash and cash equivalents of $131.5 million, against $173.3 million a year earlier (-24.1%). Source: the 20-F filed with the SEC on Apr 4, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1830749&period_type=annual&limit=5"Information only, not investment advice.